Agios Pharmaceuticals (NASDAQ:AGIO) Share Price Passes Below Two Hundred Day Moving Average – Here’s What Happened

Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) passed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $32.19 and traded as low as $29.03. Agios Pharmaceuticals shares last traded at $29.61, with a volume of 821,013 shares changing hands.

Agios Pharmaceuticals News Roundup

Here are the key news stories impacting Agios Pharmaceuticals this week:

• Positive Sentiment: FDA engagement moves mitapivat toward accelerated approval in sickle cell disease — Agios completed a pre-sNDA meeting with the FDA, plans to submit an sNDA in the coming months and has already proposed the confirmatory trial required under accelerated approval. This materially improves the probability and timeline for a new indication and is the main catalyst behind the rally. Agios Advances Mitapivat Toward Potential U.S. Accelerated Approval
• Positive Sentiment: Market reaction and analyst coverage reflect the FDA progress — multiple outlets report a sharp share-price jump (double-digit intraday gains) as investors price in a faster approval path for mitapivat. Elevated trading volume supports conviction behind the move. AGIO Rises on Mitapivat Progress Toward Accelerated Approval in SCD
• Positive Sentiment: Commercial progress in thalassemia — early uptake of Aqvesme shows physician interest (roughly one-third of patients identified as candidates), supporting Agios’s commercial execution beyond mitapivat. This diversification of revenue/relevance is supportive for medium‑term growth. PK Activation Gains Momentum in Thalassemia
• Neutral Sentiment: Insider selling noted — a recent small insider sale was reported; coverage frames it as contextual rather than signaling a material change to company prospects. Investors should compare size/frequency of insider transactions before reading into it. Insider Sells AGIO Shares Worth $82,000 — But Context Is Everything
• Negative Sentiment: Two law firms have opened investigations into Agios related to prior disclosures around the RISE UP mitapivat trial — potential securities‑litigation risk could pressure the stock if claims advance. This increases legal overhang and uncertainty despite the recent regulatory progress. Levi & Korsinsky Investigation Notice Gross Law Firm Investigation Notice
• Negative Sentiment: Goldman Sachs raised its price target to $32 but kept a “neutral” rating — the new PT is below the current market level, implying limited near‑term upside from this analyst and adding a cautious signal despite the FDA news. Goldman Sachs price target note
• Negative Sentiment: Technicals show short-term strain — a report notes AGIO passed below its 200‑day moving average recently, which may attract technical selling if it fails to hold momentum after the FDA news. Stock Passes Below 200 Day Moving Average

Analyst Ratings Changes

A number of analysts have recently issued reports on the stock. HC Wainwright increased their price target on Agios Pharmaceuticals from $62.00 to $65.00 and gave the company a “buy” rating in a report on Thursday, February 12th. Wall Street Zen raised Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Sunday, March 22nd. JPMorgan Chase & Co. upped their price target on shares of Agios Pharmaceuticals from $20.00 to $25.00 and gave the company a “neutral” rating in a research report on Tuesday, January 6th. Bank of America raised their price objective on shares of Agios Pharmaceuticals from $32.00 to $34.00 and gave the stock a “buy” rating in a report on Wednesday, December 24th. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Agios Pharmaceuticals in a report on Friday, March 27th. Six research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $41.44.

Agios Pharmaceuticals Stock Performance

The stock’s fifty day moving average is $28.61 and its 200 day moving average is $32.19. The stock has a market cap of $2.00 billion, a P/E ratio of -4.81 and a beta of 0.78.

Insider Activity at Agios Pharmaceuticals

In related news, insider Tsveta Milanova sold 2,872 shares of the company’s stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $27.02, for a total value of $77,601.44. Following the completion of the sale, the insider directly owned 34,793 shares of the company’s stock, valued at $940,106.86. This represents a 7.63% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Krishnan Viswanadhan sold 2,959 shares of the firm’s stock in a transaction dated Thursday, March 5th. The shares were sold at an average price of $27.80, for a total transaction of $82,260.20. Following the transaction, the insider directly owned 5,141 shares in the company, valued at $142,919.80. This trade represents a 36.53% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 4.30% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. AQR Capital Management LLC lifted its stake in Agios Pharmaceuticals by 66.8% during the 1st quarter. AQR Capital Management LLC now owns 51,489 shares of the biopharmaceutical company’s stock valued at $1,498,000 after acquiring an additional 20,625 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Agios Pharmaceuticals by 7.2% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,327 shares of the biopharmaceutical company’s stock valued at $1,274,000 after purchasing an additional 2,920 shares during the period. NewEdge Advisors LLC purchased a new stake in Agios Pharmaceuticals in the first quarter valued at $40,000. Goldman Sachs Group Inc. grew its position in Agios Pharmaceuticals by 16.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 658,652 shares of the biopharmaceutical company’s stock worth $19,299,000 after purchasing an additional 91,482 shares during the period. Finally, Woodline Partners LP purchased a new position in shares of Agios Pharmaceuticals during the 1st quarter valued at about $597,000.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.